slides · global inventory
Source Note
Component collection for the active corpus filters, with each row opening the slide detail view.
Matching slides 110,387
Current window 10,771-10,800
Pages 3,680
Rows per page 30
Component
10,771-10,800 of 110,387
13
The chart shows a clear shift from corporate-dominated M&A to increased VC and PE participation over the decade.Mergers and Acquisitions in LatAm: Evolution and prospects · L.E.K.
Consulting deck Strategy consulting Beat · SatisfactionLoop · Zoom In1 hit
14
The slide uses a process-flow style to link acquirers to targets and their strategic context.Mergers and Acquisitions in LatAm: Evolution and prospects · L.E.K.
Consulting deck Strategy consulting Beat · SatisfactionLoop · Zoom In1 hit
15
The slide uses a clear visual structure to map acquirers to targets and provides bulleted summaries for each transaction.Mergers and Acquisitions in LatAm: Evolution and prospects · L.E.K.
Consulting deck Strategy consulting Beat · SatisfactionLoop · Zoom In1 hit
16
The slide uses a hub-and-spoke style layout to connect PE firms to their specific portfolio acquisitions.Mergers and Acquisitions in LatAm: Evolution and prospects · L.E.K.
Consulting deck Strategy consulting Beat · SatisfactionLoop · Zoom In1 hit
17
The slide highlights international VC activity in the Brazilian market.Mergers and Acquisitions in LatAm: Evolution and prospects · L.E.K.
Consulting deck Strategy consulting 1 hit
20
The chart shows a significant decline in 2023 compared to previous years.Mergers and Acquisitions in LatAm: Evolution and prospects · L.E.K.
Consulting deck Strategy consulting 1 hit
21
The slide uses a stacked bar chart to show the composition of M&A deals in Mexico over a decade, accompanied by a table of CAGR metrics and a list of qualitative highlights.Mergers and Acquisitions in LatAm: Evolution and prospects · L.E.K.
Consulting deck Strategy consulting 1 hit
22
The slide uses a process-flow style to show acquirer-target relationships.Mergers and Acquisitions in LatAm: Evolution and prospects · L.E.K.
Consulting deck Strategy consulting 1 hit
23
The slide uses a case study format to highlight market activity.Mergers and Acquisitions in LatAm: Evolution and prospects · L.E.K.
Consulting deck Strategy consulting 1 hit
24
Includes a footer with additional relevant deals and source attribution.Mergers and Acquisitions in LatAm: Evolution and prospects · L.E.K.
Consulting deck Strategy consulting 1 hit
29
The chart shows a clear peak in deal volume in 2018 followed by a decline, with a specific callout for a 30% drop between 2021 and 2023.Mergers and Acquisitions in LatAm: Evolution and prospects · L.E.K.
Consulting deck Strategy consulting Beat · Action1 hit
30
The chart highlights the dominance of the Oil, Gas, Energy, and Mining sector, while TMT's share increases over time. A callout indicates a -24% change between 2021 and 2022.Mergers and Acquisitions in LatAm: Evolution and prospects · L.E.K.
Consulting deck Strategy consulting Beat · Action1 hit
04
Data shows hospital-related services as the primary driver of recent healthcare inflation.Perspectives on US Healthcare Inflation Insights from L.E.K. Consulting · L.E.K. Consulting
Consulting deck Strategy consulting Beat · Problem & ComplicationLoop · Mece Breakdown1 hit
05
The chart uses a grouped bar structure to compare annual inflation trends across 12 specific healthcare sub-segments.Perspectives on US Healthcare Inflation Insights from L.E.K. Consulting · L.E.K. Consulting
Consulting deck Strategy consulting Beat · Problem & ComplicationLoop · Mece Breakdown1 hit
07
The slide uses a side-by-side comparison framework to contrast opposing economic forces.Perspectives on US Healthcare Inflation Insights from L.E.K. Consulting · L.E.K. Consulting
Consulting deck Strategy consulting Beat · Evidence & ProofLoop · Cost Of Inaction1 hit
08
The chart highlights a divergence between healthcare inflation and general inflation, with a specific forecast range for healthcare.Perspectives on US Healthcare Inflation Insights from L.E.K. Consulting · L.E.K. Consulting
Consulting deck Strategy consulting Beat · Impact & Next StepsLoop · Cost Of Inaction1 hit
09
The slide uses a vertical arrow to indicate a progression from 'Nearer-term/Lower potential impact' to 'Longer-term/Greater potential impact'.Perspectives on US Healthcare Inflation Insights from L.E.K. Consulting · L.E.K. Consulting
Consulting deck Strategy consulting Beat · Impact & Next StepsLoop · Cost Of Inaction1 hit
10
The slide uses a vertical arrow to indicate a progression from 'Nearer-term/Lower potential impact' to 'Longer-term/Greater potential impact'.Perspectives on US Healthcare Inflation Insights from L.E.K. Consulting · L.E.K. Consulting
Consulting deck Strategy consulting Beat · Impact & Next StepsLoop · Cost Of Inaction1 hit
11
The slide uses a vertical arrow to indicate a progression from 'Nearer-term/Lower potential impact' to 'Longer-term/Greater potential impact'.Perspectives on US Healthcare Inflation Insights from L.E.K. Consulting · L.E.K. Consulting
Consulting deck Strategy consulting Beat · Solution & Approach1 hit
05
The table is segmented into three thematic blocks: demographics, economic indicators, and healthcare market metrics.Pivoting to a High Quality Growth of Clinical Trials in China PharmaDJ x L.E.K. Clinical Development Report · L.E.K.
Consulting deck Strategy consulting Beat · Situation & Context1 hit
07
The slide uses a comparative bar chart structure to contrast high growth in China (29% CAGR) against stable growth in the U.S. (3% CAGR).Pivoting to a High Quality Growth of Clinical Trials in China PharmaDJ x L.E.K. Clinical Development Report · L.E.K.
Consulting deck Strategy consulting Beat · Problem & Complication1 hit
08
The slide uses a honeycomb layout to group regulatory initiatives. Color coding indicates the nature of the policy (R&D, Registration, Pricing/Market Access, Commercialization).Pivoting to a High Quality Growth of Clinical Trials in China PharmaDJ x L.E.K. Clinical Development Report · L.E.K.
Consulting deck Strategy consulting Beat · Problem & Complication1 hit
10
Data refers to enterprises above designated annual revenue size (>20M RMB). Exchange rate 6.25 used.Pivoting to a High Quality Growth of Clinical Trials in China PharmaDJ x L.E.K. Clinical Development Report · L.E.K.
Consulting deck Strategy consulting Beat · Problem & Complication1 hit
11
Pivoting to a High Quality Growth of Clinical Trials in China PharmaDJ x L.E.K. Clinical Development ReportPivoting to a High Quality Growth of Clinical Trials in China PharmaDJ x L.E.K. Clinical Development Report · L.E.K.
Consulting deck Strategy consulting Beat · Problem & ComplicationLoop · Cost Of Inaction1 hit
17
The chart displays 4 categories of FDA designations with stacked segments representing product types.Pivoting to a High Quality Growth of Clinical Trials in China PharmaDJ x L.E.K. Clinical Development Report · L.E.K.
Consulting deck Strategy consulting Beat · Solution & ApproachLoop · Cost Of Inaction1 hit
18
The slide highlights the 'me-too' drug development problem in China.Pivoting to a High Quality Growth of Clinical Trials in China PharmaDJ x L.E.K. Clinical Development Report · L.E.K.
Consulting deck Strategy consulting Beat · Solution & ApproachLoop · Cost Of Inaction1 hit
19
The slide uses a dual-column layout to contrast market drivers (left) with specific regulatory examples (right).Pivoting to a High Quality Growth of Clinical Trials in China PharmaDJ x L.E.K. Clinical Development Report · L.E.K.
Consulting deck Strategy consulting Beat · Solution & ApproachLoop · Cost Of Inaction1 hit
21
The slide uses stacked bar charts to show clinical trial phases over time, with CAGR annotations.Pivoting to a High Quality Growth of Clinical Trials in China PharmaDJ x L.E.K. Clinical Development Report · L.E.K.
Consulting deck Strategy consulting 1 hit
22
The slide uses a three-row structure to map strategic pillars to real-world examples and qualitative expert validation.Pivoting to a High Quality Growth of Clinical Trials in China PharmaDJ x L.E.K. Clinical Development Report · L.E.K.
Consulting deck Strategy consulting 1 hit
25
Uses a 'Past vs Future' transformation framework to illustrate strategic shift.Pivoting to a High Quality Growth of Clinical Trials in China PharmaDJ x L.E.K. Clinical Development Report · L.E.K.
Consulting deck Strategy consulting 1 hit